BOLD Boundless Bio
- 9.670
- -0.290-2.91%
Boundless Bio News
Boundless Bio Inc. Shifts Corporate Updates to IR Website
Boundless Bio, Inc. Q1 Loss Climbs
Boundless Bio | 10-Q: Quarterly report
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
Boundless Bio 1Q Loss/Shr $12.27 >BOLD
Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD
Boundless Bio 1Q Research and Development Expenses $13.1M >BOLD
Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024
SAN DIEGO--(BUSINESS WIRE)--Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with prev
Biotech Innovations Aim to Combat Soaring Cancer Diagnoses by 2050
USA News Group – An alarming trend is happening around the world, where tens of millions of progressively younger people are being diagnosed with of...
Boundless Bio Initiated at Outperform by Leerink Partners
Boundless Bio Initiated at Outperform by Leerink Partners
Boundless Bio (BOLD.US) was first covered by Leerink Partners, which gave it an superior market rating and a target price of $25.00.
Boundless Bio (BOLD.US) was first covered by Leerink Partners, which gave it an superior market rating and a target price of $25.00.
Leerink Partners Initiates Coverage On Boundless Bio With Outperform Rating, Announces Price Target of $25
Leerink Partners analyst Michael Cherny initiates coverage on Boundless Bio with a Outperform rating and announces Price Target of $25.
Boundless Bio Price Target Announced at $24.00/Share by Guggenheim
Boundless Bio Price Target Announced at $24.00/Share by Guggenheim
Analysts' Opinions Are Mixed on These NA Stocks: Boundless Bio Inc. (BOLD) and Solventum Corporation (SOLV)
Boundless Bio (BOLD.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $20.00.
Boundless Bio (BOLD.US) was first covered by Piper Sandler, which gave it an increase rating, with a target price of $20.00.
Boundless Bio Initiated at Overweight by Piper Sandler
Boundless Bio Initiated at Overweight by Piper Sandler
Piper Sandler Initiates Coverage On Boundless Bio With Overweight Rating, Announces Price Target of $20
Piper Sandler analyst Joseph Catanzaro initiates coverage on Boundless Bio (NASDAQ:BOLD) with a Overweight rating and announces Price Target of $20.
Boundless Bio Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/22/2024 50.49% Piper Sandler → $20 Initiates Coverage On → Overweight 12/09/2019 — Evercore ISI Group
Boundless Bio Doses First Patient In Phase 1/2 Clinical Trial Of BBI-825 In Cancer Patients With Resistance Gene Amplifications
Boundless Bio Doses First Patient In Phase 1/2 Clinical Trial Of BBI-825 In Cancer Patients With Resistance Gene Amplifications
Boundless Bio Presents Preclinical And Clinical Pharmacodynamic Data On Lead EcDNA-Directed Therapy, BBI-355, At AACR Annual Meeting 2024
Findings support the ongoing development of BBI-355, a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1) in Phase 1/2 development, as a differentiated treatment approach for ecDNA-enabled
Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on Its Lead Extrachromosomal DNA (EcDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024
Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, presents preclinical and clinical pharmacodynamic data on its lead ecDNA-directed therapy (ecDTx), BBI-355, and research on ecDNA-mediated acquired resistance to chemotherapy at the American Association for Cancer Research (AACR) Annual Meeting 2024.
Boundless Bio Insider Bought Shares Worth $3,200,000, According to a Recent SEC Filing
Kristina Burow, 10% Owner, Director, on April 02, 2024, executed a purchase for 200,000 shares in Boundless Bio (BOLD) for $3,200,000. Following the Form 4 filing with the SEC, Burow has control over
Analysis
Price Target
No Data
